0001209191-23-012657.txt : 20230224 0001209191-23-012657.hdr.sgml : 20230224 20230224160013 ACCESSION NUMBER: 0001209191-23-012657 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230221 FILED AS OF DATE: 20230224 DATE AS OF CHANGE: 20230224 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: BREITMEYER JAMES B CENTRAL INDEX KEY: 0001244823 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-50549 FILM NUMBER: 23666813 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Oncternal Therapeutics, Inc. CENTRAL INDEX KEY: 0001260990 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 621715807 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 12230 EL CAMINO REAL STREET 2: SUITE 230 CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: (858) 434-1113 MAIL ADDRESS: STREET 1: 12230 EL CAMINO REAL STREET 2: SUITE 230 CITY: SAN DIEGO STATE: CA ZIP: 92130 FORMER COMPANY: FORMER CONFORMED NAME: GTX INC /DE/ DATE OF NAME CHANGE: 20030822 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2023-02-21 0 0001260990 Oncternal Therapeutics, Inc. ONCT 0001244823 BREITMEYER JAMES B 12230 EL CAMINO REAL, SUITE 230 SAN DIEGO CA 92130 1 1 0 0 Chief Executive Officer Stock Option 0.96 2023-02-21 4 A 0 650000 0.00 A 2033-02-21 Common Stock 650000 650000 D Stock Option 0.96 2023-02-21 4 A 0 65000 0.00 A 2023-02-21 Common Stock 65000 65000 I By Spouse Stock Option 0.81 2023-02-21 4 A 0 42196 0.00 A 2028-11-14 Common Stock 42196 42196 D 25% of the shares subject to the stock option vest on first anniversary of the date of grant, and the remaining shares subject to the option vest in 36 equal monthly installments, subject to the recipient's continued employment or service with the Issuer on each such date. On November 14, 2018, the recipient received a stock option to purchase 168,787 shares, which vest on the achievement of certain pre-established strategic milestones. The issuer's Compensation Committee determined that two such strategic milestones were achieved, resulting in the vesting of 42,196 shares subject to the stock option effective February 21, 2023. 21,098 shares subject to the option remain unvested. /s/Chase C. Leavitt, Attorney-in-fact 2023-02-24